menu
    • menu
    [{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CRG-022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"CARGO Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"CRG-022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"CARGO Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARGO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by CARGO Therapeutics

    Menu

    CARGO Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CARGO Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            CARGO Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRG-022

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $281.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            CARGO Therapeutics Announces Pricing of Initial Public Offering

                            Details : The net proceeds will be used to fund the development of CRG-022, an autologous CAR T-cell product candidate that targets CD22, currently in Phase I for Marginal Zone B-cell Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 11, 2023

                            Lead Product(s) : CRG-022

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $281.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CARGO Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            CARGO Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CARGO Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            CARGO Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRG-022

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Third Rock Ventures

                            Deal Size : $200.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline o...

                            Details : The proceeds from the financing will be used to advance CARGO’s autologous CD22 CAR T-cell therapy candidate, CRG-022, through a pivotal multicenter Phase 2 trial in patients with LBCL whose disease has relapsed or is refractory to CD19 CAR T-cell ther...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : CRG-022

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Third Rock Ventures

                            Deal Size : $200.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth